A neurologist's personal battle against Alzheimer's disease
In an important new study published yesterday in Nature and described in a more accessible form today in the New York Times, researchers studied MRI scans of 785 participants in the UK Biobank. All of these volunteers had...
On August 21, 2017 I witnessed my first and likely my last solar eclipse. Of course, I had read about the mystical power of totality. I came across it for the first time when I...
As I describe in Tattoo, my first symptom of Alzheimer’s occurred over fifteen years ago when I first noticed a decrease in my ability to smell and then began to have episodes of illusory odors...
Music has been an important part of my life, almost from the beginning. My mother was a very good, amateur pianist, and I have early memories of trying to emulate her playing. By age...
Abnormal tau protein found in neurofibrillary tangles can be found in the brain at least several years before the onset of cognitive impairment in Alzheimer’s disease. Now a fascinating Dutch study of 78 cognitively normal,...
Wendy Mitchell, in her wonderful book Somebody I Used to Know: A Memoir, tells of her frustration when asking her supervisors in the UK National Health Service for accommodation for her early-onset Alzheimer’s disease. Wendy...
Ten days ago, officials at the Centers for Medicare and Medicaid Services (CMS) announced that Medicare coverage for Aduhelm (aducanumab) would apply only to patients participating in approved clinical trials. Recall that on June...
The National Alzheimer’s Project Act (NAPA) was signed into law by President Obama on January 4, 2011. The act created the National Plan to Address Alzheimer’s Disease (and related dementias). The plan has been updated annually,...
Our vision appears to have a complicated relationship to dementia. Posterior cortical atrophy is a rare variant of Alzheimer’s disease in which the amyloid plaques and neurofibrillary tangles first form in the back of...
Perhaps the biggest Alzheimer’s news in 2021 was the controversial FDA approval of the anti-amyloid monoclonal antibody Aduhelm (aducanumab). Controversy surrounds the mixed results of two parallel phase 3 trials. Both trials showed efficacy at removing...
Recent Comments